Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCIDITY: Avexitide in Post-Bariatric Hypoglycemia
NCT06747468Phase 3Active, not recruiting
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-bariatric hypoglycemia (PBH) comparing AVEXITIDE with PLACEBO (2 arms). Primary endpoints: Composite rate of Level 2 and Level 3 hypoglycemic events at 16 weeks, Safety and Tolerability of avexitide at 16 weeks and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
exendin 9-39
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT06747468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747468.